Author Archives: Nello Mainolfi

Targeted Protein Degradation: The First Proof-of-Mechanism in a Randomized, Placebo-Controlled Study
July 6, 2021

By Nello Mainolfi, PhD, Co-Founder, President and CEO of Kymera Therapeutics, as part of the From The Trenches feature of LifeSciVC. The inherent ability to combine the power of genetic-like knockdown with the flexibility of small molecules; the power to

Leave a comment

Targeted Protein Degradation Comes of Age
May 15, 2019

This blog was written by Nello Mainolfi, CSO and co-founder of Kymera Therapeutics, as part of the From The Trenches feature of LifeSciVC. Translation of well validated biology into therapeutics remains one of the biggest challenges of modern drug development,

Leave a comment